Login Register Cart 0
Generic placeholder image

Drug Metabolism and Bioanalysis Letters

Editor-in-Chief

ISSN (Print): 2949-6810
ISSN (Online): 2949-6829

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Research Article

Stability Indicating Method Development and Validation for the Estimation of Bempedoic Acid by RP-HPLC

Author(s): Mansi V. Chaudhari, Ujwal Chaudhari, Jagdish K. Sahu* and Shashikant B. Bagade

Volume 17, Issue 1, 2024

Published on: 16 April, 2024

Page: [23 - 33] Pages: 11

DOI: 10.2174/0118723128278080240404052506

Price: $65

Abstract

Background: Bempedoic acid (BEM) belongs to a category of drugs known as Adenosine triphosphate-citrate Lyase (ACL) inhibitors. It is a prodrug with intracellular activation that is administered orally. Bempedoic acid is used to treat existing atherosclerotic cardiovascular diseases, mainly hypercholesterolemia.

Methods: For the stability-indicating assay, the HPLC method was employed using a Kromasil 100-5-C8 column (100 mm × 4.6 mm), a UV detector set at 230 nm, and a mobile phase comprising a 70:30 v/v mixture of acetonitrile and 0.1% Orthophosphoric Acid (OPA) buffer. The method was operated at an ambient temperature with a flow rate of 1 mL/min. The method developed has been statistically validated according to ICH guidelines.

Results: The stability-indicating method was executed using a Kromasil 100-5-C8 (100 mm × 4.6 mm) column at a 1.0 mL/min flow rate. A mixture of acetonitrile and 0.1% Orthophosphoric Acid (OPA) buffer in a 70:30 v/v ratio made up the mobile phase. BEM's retention times were discovered to be 1.88 minutes each. The temperature was kept at room temperature. 234 nm was the ideal wavelength for BEM. According to ICH criteria, the approach developed has undergone statistical validation. BEM's % RSD was discovered to be 0.6, respectively. For BEM, the % recovery was determined to be 100.0%. Regression models for bempedoic acid yielded LoD and LoQ values of 3.3 and 10.1 g/mL, respectively. The method showed good reproducibility and recovery with a % RSD less than 2. Studies on forced degradation confirmed the method's capacity to indicate stability in the presence of stress conditions, such as acid, basic, peroxide, UV, heat, and humidity. Both the retention times and the run time were shortened.

Conclusion: In accordance with ICH Q2 (R1) guidelines, this method was successfully tested with HPLC to confirm the chemical structures of newly produced degradation products of bempedoic acid.

« Previous Next »
Graphical Abstract

[1]
Agarwala A, Goldberg AC. Bempedoic acid: A promising novel agent for LDL-C lowering. Future Cardiol 2020; 16(5): 361-71.
[http://dx.doi.org/10.2217/fca-2020-0016] [PMID: 32463301]
[2]
US Food and Drug Administration. NEXLETOL (Bempedoic Acid) tablet for oral use 2020.
[3]
Feng X, Zhang L, Xu S, Shen A. ATP-citrate lyase (ACLY) in lipid metabolism and atherosclerosis: An updated review. Prog Lipid Res 2020; 77: 101006.
[http://dx.doi.org/10.1016/j.plipres.2019.101006] [PMID: 31499095]
[4]
Chauhan A, Harti Mittu B, Chauhan P. Analytical method development and validation: A concise review. J Anal Bioanal Tech 2015; 6(233): 2.
[http://dx.doi.org/10.4172/2155-9872.1000233]
[5]
Uslu B, Lingeman H, Ozkan SA, Palit M, Dogan-Topal B. Analytical method development and validation of pharmaceutical analysis using chromatographic techniques. Chromatogr Res Int 2012; 2012: 1-1.
[http://dx.doi.org/10.1155/2012/948129]
[6]
Sharma S, Goyal S, Chauhan K. A review on analytical method development and validation. Int J Applied Pharm 2018; 10(6): 8.
[http://dx.doi.org/10.22159/ijap.2018v10i6.28279]
[7]
Toomula N, Arun K, Satish KD, Vijaya SB. Development and validation of analytical methods for pharmaceuticals. J Anal Bioanal Tech 2011; 2(5): 127.
[http://dx.doi.org/10.4172/2155-9872.1000127]
[8]
Lakshmi K, Rajesh T. Determination of voglibose in pharmaceutical formulations by high performance liquid chromatography using refractive index detection. Eur J Chem 2010; 1(4): 262-5.
[http://dx.doi.org/10.5155/eurjchem.1.4.262-265.116]
[9]
Mihaylova B, Emberson J, Blackwell L, et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012; 380(9841): 581-90.
[http://dx.doi.org/10.1016/S0140-6736(12)60367-5 ] [PMID: 22607822]
[10]
Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019; 140(11): e596-646.
[http://dx.doi.org/10.1161/CIR.0000000000000678 ] [PMID: 30879355]
[11]
Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: A report of the american college of cardiology/american heart association task force on clinical practice guidelines. Circulation 2019; 139(25): e1082-143.
[http://dx.doi.org/10.1161/CIR.0000000000000625] [PMID: 30586774]
[12]
Yang J. Bempedoic acid for the treatment of hypercholesterolemia. Expert Rev Cardiovasc Ther 2020; 18(7): 373-80.
[http://dx.doi.org/10.1080/14779072.2020.1782744 ] [PMID: 32532162]
[13]
Karla VR, Raghasudha M, Chitta R. Simultaneous determination of bempedoic acid and ezetimibe in rat plasma using hplc–pda and its applications to a pharmacokinetic study. Chemistry Africa 2022; 5(4): 917-27.
[http://dx.doi.org/10.1007/s42250-022-00392-7]
[14]
Markham A. Bempedoic acid: First approval. Drugs 2020; 80(7): 747-53.
[http://dx.doi.org/10.1007/s40265-020-01308-w] [PMID: 32314225]
[15]
Lalwani ND, Hanselman JC, MacDougall DE, Sterling LR, Cramer CT. Complementary low-density lipoprotein-cholesterol lowering and pharmacokinetics of adding bempedoic acid (ETC-1002) to high-dose atorvastatin background therapy in hypercholesterolemic patients: A randomized placebo-controlled trial. J Clin Lipidol 2019; 13(4): 568-79.
[http://dx.doi.org/10.1016/j.jacl.2019.05.003 ] [PMID: 31202641]
[16]
Biolo G, Vinci P, Mangogna A, et al. Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome. Front Cardiovasc Med 2022; 9: 1028355.
[http://dx.doi.org/10.3389/fcvm.2022.1028355 ] [PMID: 36386319]
[17]
Gunn LH, McKay AJ, Feng A, Louie MJ, Ballantyne CM, Ray KK. Estimated cardiovascular benefits of bempedoic acid in patients with established cardiovascular disease. Atherosclerosis Plus 2022; 49: 20-7.
[http://dx.doi.org/10.1016/j.athplu.2022.05.003 ] [PMID: 36644205]
[18]
Molleti D, Amgoth KP, Pallekona S. Stability indicating method development and validation for the estimation of bempedoic acid and ezetimibe by reverse phase– ultra performance liquid chromatography. Int J Pharm Sci Drug Res 2021; 13(5): 559-64.
[http://dx.doi.org/10.25004/IJPSDR.2021.130514]
[19]
Yarra UST, Gummadi S. Stability indicating RP-UPLC method for simultaneous quantification of bempedoic acid and ezetimibe in bulk and pharmaceutical formulations. Future J Pharmac Sci 2021; 7(1): 209.
[http://dx.doi.org/10.1186/s43094-021-00363-8]
[20]
Vejendla A, Talari S, Ramu G, Rajani C. Characterization of novel stress degradation products of Bempedoic acid and Ezetimibe using UPLC MS/MS  Development and validation of stability indicating UPLC method. Fut J Pharmac Sci 2021; 7: 234.
[http://dx.doi.org/10.1186/s43094-021-00381-6]
[21]
Gaikwad J, Sharma S, Hatware KV. Review on characteristics and analytical methods of tazarotene: An update. Crit Rev Anal Chem 2020; 50(1): 90-6.
[http://dx.doi.org/10.1080/10408347.2019.1586519 ] [PMID: 30942085]
[22]
Chaudhari U, Sahu JK, Dande PR. Analytical method development, validation and forced degradation study of dapagliflozin by RP-HPLC. Drug Metabo Bioanaly Lett 2023; 16(2): 140-52.
[http://dx.doi.org/10.2174/2949681016666230823091112 ] [PMID: 37612872]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy